title: Immune checkpoint blockade - a treatment for urological cancers?
authors.affiliation: Medical Research Council (MRC) Centre for Transplantation, King's College London and Guy's Hospital, London, UK. oelhage@yahoo.com.
authors.forename: Oussama
authors.initials: O
authors.lastname: Elhage
authors.affiliation: Medical Research Council (MRC) Centre for Transplantation, King's College London and Guy's Hospital, London, UK.
authors.forename: Christine
authors.initials: C
authors.lastname: Galustian
authors.affiliation: Medical Research Council (MRC) Centre for Transplantation, King's College London and Guy's Hospital, London, UK.|National Institute for Health Research (NIHR) Biomedical Research Centre, King's Health Partners, King's College London and Guy's Hospital, London, UK.
authors.forename: Prokar
authors.initials: P
authors.lastname: Dasgupta
mesh_terms: D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D059447:Cell Cycle Checkpoints / Q000187:drug effects* / Q000276:immunology*; D003362:Cost-Benefit Analysis; D006801:Humans; D007167:Immunotherapy / Q000191:economics / Q000379:methods*; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor